文献速递肿瘤 PET/CT核素与放射性配体治疗

生长抑素受体异质性对Lu-177 DOTATOC/DOTATATE治疗进展期NET的预后意义

Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-08-14

该回顾性研究分析了65例接受至少2周期Lu-177 DOTATOC或DOTATATE治疗的进展期1/2级神经内分泌肿瘤患者,基线Ga-68 DOTATATE/DOTATOC PET/CT视觉评估SSTR表达异质性。异质性患者28例(44.4%),均质35例(55.6%)。中位随访25个月,异质性组总生存期和无进展时间均显著更短,多因素分析显示SSTR异质性是OS和TTP的唯一预后因素。

要点

  • 视觉评估SSTR PET/CT异质性可预测PRRT疗效和预后。
  • 异质性患者中位TTP为26个月,均质患者为54个月。
  • SSTR异质性是OS(HR=3.68)和TTP(HR=3.09)的独立预后因素。

核心结论

  • 视觉评估SSTR异质性对接受PRRT的进展期1/2级NET患者具有预测和预后价值。

研究设计与样本

  • 回顾性分析65例(25女,40男;65±11岁)进展期1/2级NET患者,接受2-5周期PRRT,平均给药剂量6.6±0.97 GBq Lu-177 DOTATOC或DOTATATE。
  • 所有患者基线行Ga-68 DOTATATE或Ga-68 DOTATOC PET/CT,视觉评估索引病灶SSTR表达异质性。
  • 首次PRRT后中位随访25个月(范围5-77个月)。

主要发现

  • 70%患者接受3周期或以上治疗;40%为一线或二线,60%为三线或以上。
  • SSTR表达异质性28例(44.4%),均质性35例(55.6%)。
  • 疾病稳定23例(35.4%),部分缓解17例(26.1%),疾病进展25例(38.5%)。
  • 中位OS未达到,全队列24个月生存率83%。
  • 单因素分析中影响OS的因素包括类癌心脏病、类癌综合征和SSTR表达质量(p<0.05);异质性患者OS显著更低(p=0.01)。

临床怎么用

  • 对拟行PRRT的进展期1/2级NET患者,基线SSTR PET/CT应视觉评估病灶异质性以辅助预后分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: One of the primary prerequisites for peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumors (NET) is the presence of somatostatin receptors (SSTR) on NET cells. NET are highly heterogeneous and an individual patient as well as separate metastases can harbor cells with different clones, which influence the SSTR expression on NET cells. With this background we looked into our institutional database to assess the prognostic significance of quality of SSTR expression on SSTR PET/CT imaging in patients treated with at least two cycles of Lu-177 DOTATOC or Lu-177 DOTATATE. METHOD: Clinical reports and images from 65 (25 females, 40 males; 65 ± 11 years old) patients with progressive grade 1 or grade 2 NET with 2-5 therapy cycles of PRRT with an average administered dose of 6.6 ± 0.97 GBq Lu-177 DOTATOC or Lu-177 DOTATATE were analyzed. All patients were examined with baseline Ga-68 DOTATATE or Ga-68 DOTATOC PET/CT (PET). Quality of SSTR expression as a measure of heterogeneity on indexed lesions was assessed visually. Patients were followed for a median duration of 25 months after the first PRRT (range 5-77 months). RESULTS: A total of 70% of the patients received three or more therapy cycles. Twenty-six patients (40%) were treated with PRRT as first or second line while 39 (60%) as third line or more. SSTR expression was heterogeneous in 28 (44.4%) and homogeneous in 35 (55.6%) patients. Disease stabilization could be achieved in 23 patients (35.4%), whereas 17 (26.1%) showed partial remission and 25 patients (38.5%) had disease progression. Median OS was not reached. The 24-month survival rate of the whole study cohort was 83%. In univariate analyses, factors influencing OS were carcinoid heart disease, carcinoid syndrome and quality of SSTR expression (p < 0.05). Patients with heterogeneous SSTR expression on target lesions had a significantly lower OS (p = 0.01). Median time to progression in total patient population was found to be 40 months. Patients with heterogeneous SSTR expression on target lesions had significantly lower TTP (26 months vs 54 months log Rank p = 0.013). By multivariate analyses, quality of SSTR was found to be the only prognostic factor for OS (p = 0.04; HR = 3.68) and also for TTP (p = 0.03; HR = 3.09). CONCLUSION: Visual assessment of SSTR heterogeneity has both predictive and prognostic value in progressive grade 1 or grade 2 NET patients undergoing PRRT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Graf J, Pape UF, Jann H, et al. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging. 2019. PMID: 31414209. doi:10.1007/s00259-019-04439-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。